Sort   by:  
 Page size 
UnknownIdentification of seven new prostate cancer susceptibility loci through a genome-wide association study.
Not available
S-EPMC2846760 | biostudies-literature
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownEffects of medical therapies on retinopathy progression in type 2 diabetes.
Not available
S-EPMC4026164 | biostudies-literature
UnknownSafety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Not available
S-EPMC8639161 | biostudies-literature
UnknownClinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.
Not available
S-EPMC10346130 | biostudies-literature
UnknownSARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.
Not available
S-EPMC11117088 | biostudies-literature
UnknownRisk of COVID-19 after natural infection or vaccination.
Not available
S-EPMC10518569 | biostudies-literature
Sort   by:  
 Page size